Compare Heron Therapeutics Inc (HRTX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kimberly Clark Corp — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Kimberly Clark Corp trades at $97.53 (market cap $32.51B). The key difference: Kimberly Clark Corp is far larger — about 478× Heron Therapeutics Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kimberly Clark Corp for 93 Days on average.
| HRTX | KMB | |
|---|---|---|
Market Cap | $68.01M | $32.51B |
Volume | 1,891,941 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $121.44 |
52-Week Low | $0.27 | $93.05 |
Typical Hold Time | 35 Days | 93 Days |
Enterprise Value | $174.75M | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Kimberly-Clark (KMB) trades at $96.48, down 0.3% on the day, showing bearish technical signals with the current price near support at $96. The company maintains strong profitability with 11.79% net margins and has beaten earnings estimates in 2 of the last 3 quarters, though Q2 2026 missed expectations. Recent executive transitions and the pending Kenvue acquisition create both strategic opportunities and integration risks.
KMB offers a compelling 5.3% dividend yield with 54 consecutive years of increases, but cash flow concerns and acquisition-related debt pose sustainability questions. Analyst consensus remains cautiously optimistic with a $117.25 price target suggesting 21% upside, though the stock faces near-term headwinds from technical weakness and merger execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
